Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
about
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadAssessing predicted HIV-1 replicative capacity in a clinical settingDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyPersistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionAntiretroviral therapy in the clinicAssociation of HIV/AIDS Clinician Warm Line Utilization with Diagnosis and Management of Antiretroviral Treatment Failure in Mozambique: A Retrospective Analysis of Program DataMissing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men.Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort studyReplicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia.First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.The role of toxicity-related regimen changes in the development of antiretroviral resistanceTrends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN TrialLong-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modificationAntiretroviral therapy of late presenters with advanced HIV disease.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsA Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.How effectively can HIV phylogenies be used to measure heritability?Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Causes and consequences of incomplete HIV RNA suppression in clinical trials.When can HIV clinical trials detect treatment effects on drug resistance?Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan.Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
P2860
Q28475652-92DD5BD3-C9EE-434B-AB68-73928EF8DD6BQ28477801-0F4A1CB9-5174-48C5-951F-3DD926AC514BQ28478666-C2749B02-675D-444C-8055-B3C5C1D33F93Q28482138-0E6AAF42-CC9F-4C16-A769-C28C1619149CQ28485321-0AF48614-59B3-406D-9ED1-F45961C8BCFEQ28534423-F4A0A09E-A971-4B81-806A-D2335AAACD72Q28536153-DC701763-FF82-4979-859C-6B6FD1DC37F6Q28538326-D177DC3A-D5A8-48EE-BE13-F99BF535AFC0Q28544845-9F3AF773-9AD8-49C3-AC00-ACCAD3F3AC70Q28728304-2A36E23F-FCDE-411C-9F21-3C15F94542E7Q28748901-4B20F114-5D87-408F-9CAE-BA68E3082084Q33877347-8FCF58A0-AA40-451A-8894-27A0717145E3Q33904819-680EE90B-262E-4799-8AD5-A197083E7037Q33981074-9D5A07E3-A224-4112-AD61-03C2706538ABQ34113502-A8232B66-2EEB-499B-A588-890648B01F46Q34129231-67CC51D5-81EE-4912-9FAD-E7B6912A429CQ34292138-68B5547A-706E-4745-BF82-FAF77B5A21FAQ34547116-7A6C1712-9F75-48B5-805A-629D08160D2BQ34604408-69D95738-90A0-484D-8B10-B07652677007Q34662575-941C2BBA-A543-47BE-98F3-5A09B37D8C5FQ34699175-8CCA00E3-88D6-40E9-BAFD-D135FE5CE3C0Q34730686-6A74AEFE-F98B-4969-9917-5074C44A0D18Q35034306-800656C0-4DE6-4AF2-A086-32E0DB5DB079Q35057734-3289B713-306B-44AA-AE9A-015E053689E4Q35330053-5C6ADFE6-C208-4A03-BCE9-50799B7FD2AEQ35949742-D17628AD-2B6F-40DC-B7DD-2E83AC8DF1F9Q36013412-6793579D-5CB9-4588-A1B0-6B3D1C4A1347Q37003795-204FA05C-E97C-4D86-9ECD-B0F366EEEAB8Q37137218-87D83693-C679-44F9-808B-990AA3C27E41Q37189622-800939F2-7AE6-46BF-9881-630E3F72F102Q37216235-95EEFF19-F909-41EC-B4AF-BCFAAD0D0777Q37228748-CF214AE8-4B60-4C9E-A3F4-22D6F6CC60F0Q37233074-DF9BE688-A99B-4D73-BB77-3979829CA2F8Q37264576-6A52618D-DC05-4756-B178-4B65807D9242Q37363152-A4B4E2F9-4939-40D9-A354-6C953846ACF9Q37475726-3404C5A5-F979-401A-AF4C-06651D8586ACQ37631282-24670871-4FE6-4F30-9F1F-CBB17A4FC497Q38215850-7B2F03C4-1D82-4552-AF0E-FFF268EB5433Q38405467-9B89B042-D3B5-4586-BA55-B8AA0C085340Q39080554-496EEBCE-2237-4396-A9D6-0F08850B797F
P2860
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Emergence of HIV-1 drug resist ...... on of different regimen types.
@en
type
label
Emergence of HIV-1 drug resist ...... on of different regimen types.
@en
prefLabel
Emergence of HIV-1 drug resist ...... on of different regimen types.
@en
P2093
P50
P1476
Emergence of HIV-1 drug resist ...... on of different regimen types.
@en
P2093
Amalio Telenti
Bruno Ledergerber
Luc Perrin
Martin Rickenbach
Philippe Bürgisser
Pietro L Vernazza
P304
P356
10.1001/ARCHINTE.167.16.1782
P407
P50
P577
2007-09-01T00:00:00Z